Skip to main content
Top

02-03-2024 | Review

European Lipid Guidelines and Cardiovascular Risk Estimation: Current Status and Future Challenges

Authors: Angela Pirillo, Lale Tokgözoğlu, Alberico L. Catapano

Published in: Current Atherosclerosis Reports

Login to get access

Abstract

Purpose of Review

Genetic, experimental, epidemiologic, and clinical data support the causal role of elevated levels of low-density lipoprotein cholesterol (LDL-C) in atherosclerosis and cardiovascular disease (CVD). The recommendations of the 2019 European guidelines are based on the concept of differential CV risk, which in turn defines the LDL-C goals that should be achieved.

Recent Findings

The 2019 ESC/EAS guidelines for dyslipidaemia use the Systematic COronary Risk Evaluation (SCORE) model to assess CV risk, which provides a 10-year risk of fatal CV event. The SCORE model has recently been updated to reflect current rates of cardiovascular disease in Europe. The new SCORE2 model provides estimates of the 10-year risk of fatal and non-fatal CVD events in people aged 40–69 years, thus improving the identification of individuals at higher risk of a CVD event. However, as in the SCORE age is the main determinant of risk, young people have a relatively low estimated 10-year risk of a CV event even with high levels of one or more causal risk factors. Individuals with familial hypercholesterolaemia, who have elevated LDL-C levels from birth and have a high risk of premature CVD, are one example. The concept of cumulative LDL exposure is thus becoming increasingly important. This is also supported by Mendelian randomisation studies showing that carrying genetic variants associated with lower LDL-C levels reduces CV risk.

Summary

These observations have introduced the concept of “cholesterol-years”, which takes into account both LDL-C levels and time of exposure. It is crucial that future European guidelines pay more attention to this point.
Literature
4.
go back to reference Catapano AL, Graham I, De Backer G, et al: 2016 ESC/EAS guidelines for the management of dyslipidaemias: the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) developed with the special contribution of the European Assocciation for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J 2016, 37(39):2999-3058. /10.1093/eurheartj/ehw272 Catapano AL, Graham I, De Backer G, et al: 2016 ESC/EAS guidelines for the management of dyslipidaemias: the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) developed with the special contribution of the European Assocciation for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J 2016, 37(39):2999-3058. /10.1093/eurheartj/ehw272
7.••
go back to reference SCORE2 working group and ESC Cardiovascular risk collaboration. SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe. Eur Heart J. 2021;42(25):2439–54. https://doi.org/10.1093/eurheartj/ehab309. This paper describes the new algorithm for predicting the 10-year risk of fatal and non-fatal CVD in European populations, which aims to improve the identification of individuals at higher risk of CVD.CrossRef SCORE2 working group and ESC Cardiovascular risk collaboration. SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe. Eur Heart J. 2021;42(25):2439–54. https://​doi.​org/​10.​1093/​eurheartj/​ehab309. This paper describes the new algorithm for predicting the 10-year risk of fatal and non-fatal CVD in European populations, which aims to improve the identification of individuals at higher risk of CVD.CrossRef
13.••
go back to reference Domanski MJ, Tian X, Wu CO, et al. Time course of LDL cholesterol exposure and cardiovascular disease event risk. J Am Coll Cardiol. 2020;76(13):1507–16. https://doi.org/10.1016/j.jacc.2020.07.059. This paper shows that the risk of a future CVD event at a given age increases with the total accumulated area under the LDL-C curve as a function of age and that it is modulated by the time course of area accumulation.CrossRefPubMed Domanski MJ, Tian X, Wu CO, et al. Time course of LDL cholesterol exposure and cardiovascular disease event risk. J Am Coll Cardiol. 2020;76(13):1507–16. https://​doi.​org/​10.​1016/​j.​jacc.​2020.​07.​059. This paper shows that the risk of a future CVD event at a given age increases with the total accumulated area under the LDL-C curve as a function of age and that it is modulated by the time course of area accumulation.CrossRefPubMed
Metadata
Title
European Lipid Guidelines and Cardiovascular Risk Estimation: Current Status and Future Challenges
Authors
Angela Pirillo
Lale Tokgözoğlu
Alberico L. Catapano
Publication date
02-03-2024
Publisher
Springer US
Published in
Current Atherosclerosis Reports
Print ISSN: 1523-3804
Electronic ISSN: 1534-6242
DOI
https://doi.org/10.1007/s11883-024-01194-7
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.